Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRIDA: reparixin + paclitaxel versus paclitaxel in first-line metastatic triple-negative breast cancer
2014-004796-23Phase 2Completed
- Sponsor
- Dompé
- Start
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in triple-negative breast cancer (TNBC) and breast cancer comparing Reparixin + paclitaxel with Placebo + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Apr 2015; status: completed.
02
Drugs
reparixinpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2014-004796-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004796-23.